GeneWorks appointed Distributor for CODA Genomics

 

Thebarton, Australia, January 8, 2007—GeneWorks and CODA Genomics announced today a distribution agreement to supply researchers in Australia and New Zealand with CODA’s proprietary Translational Engineering™ protein expression technology. The companies will officially launch the relationship as a presentation at the upcoming Lorne Cancer Conference in Australia. Dr. Adams will be presenting CODA’s unique approaches at solving protein expression problems.

CODA’s proprietary protein translation technologies address protein expression, solubility and activity challenges in rational design steps at all stages of research and pharmaceutical development. This important, revolutionary utilization of synthetic biology has the potential to change the competitive landscape of many businesses which rely on successful protein production.

“We are excited about our new relationship with CODA Genomics” said Peter Guilhaus, GeneWorks Managing Director. “Our representation of CODA’s novel protein expression technologies continues our reputation as a provider of innovative and practical solutions to life scientists”.
“GeneWorks is an excellent partner for CODA in Australia and New Zealand. Their long-standing reputation will ensure a successful relationship as we continue to expand our presence overseas”, said Alan Carter, Vice President of Business Development.

About Gene Works
GeneWorks Pty. Ltd. established in 1996 is a major Australian supplier of leading edge molecular biology research products. Centrally headquartered in Adelaide, South Australia with sales offices in all Australian capital cities as well as Auckland NZ, it services and supplies the Australian and New Zealand markets with a select range of innovative leading edge equipment, reagents, consumables and associated services. GeneWorks’ core business is the synthesis and supply of custom oligonucleotides - proudly manufactured in Adelaide.

About CODA Genomics, Inc.
CODA Genomics, Inc. is a protein Translation Engineering™ company focused on proprietary, patented optimization of synthetic genes to express across a variety of eukaryotic and prokaryotic cell lines. This unique technology enables synthetic biology success by solving problems related to protein expression, activity and solubility.